The Aenova Group has opened a new production building at its Regensburg site for 25 million euros for the manufacture of highly effective drugs for cancer treatment, among other things. One of the most modern production halls for cytostatics and cytotoxics, both highly effective pharmaceutical agents against cancer, has now been opened at the Aenova Pharma site in the Regensburg bioregion. in order to be able to meet the increased global market demand for highly effective drugs.
Supply bottlenecks for certain drugs have dominated the German media for months. To meet the steadily increasing demand, Aenova, one of the world's leading development service providers and contract manufacturers for the pharmaceutical and healthcare industries, has expanded its Regensburg site with a new building for the development and production of highly potent active ingredients at a cost of around 25 million euros.
In Regensburg, the company develops and produces drugs for the treatment of inflammatory diseases such as psoriasis or arthritis, but also autoimmune diseases and cancer such as leukemia, as well as novel drugs (so-called New Chemical Entities, NCE). Special safety standards must be observed in the development and production of these highly effective active ingredients.
"We in Regensburg are part of the Aenova Group "Competence Center HPAPI & Oncology Products". The new building is an important milestone in this respect," explains Oliver Schmied, Managing Director at Aenova's Regensburg site. "Not only will we be able to better serve market needs and customer requests, but more importantly, we will be able to reliably provide vital medicines for cancer patients worldwide. We are very proud of that here."
Aenova's Regensburg site has its roots in the Heyden chemical plant, which was acquired by Bristol Myers Squibb in the 1950s. The plant's closure in the mid-1990s marked the beginning of today's contract and custom manufacturing operations. Today, the Aenova Group is one of the world's leading contract manufacturers and development service providers for the pharmaceutical and healthcare industries. The services include the complete production and development of all dosage forms, product groups and active ingredient classes from pharmaceuticals to dietary supplements.
Around 4,000 employees work for the Aenova Group at 14 sites in Europe and the USA. The number of employees at the Regensburg site has been increasing for years; most recently, around 400 people were employed here, producing over 1 billion tablets and capsules per year.